VEGFA and neoplasm: Nevertheless, anti‐PD‐1/PD‐L1 treatments might still be effective for immune‐desert or immune‐excluded tumors by activating an impaired priming phase38 and improving the trafficking of cytotoxic T cells to the tumor via the antivascular endothelial growth factor (VEGF) effects of bevacizumab.39